These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A New SV2A Ligand for Epilepsy. Rogawski MA Cell; 2016 Oct; 167(3):587. PubMed ID: 27768878 [TBL] [Abstract][Full Text] [Related]
24. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding. Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812 [TBL] [Abstract][Full Text] [Related]
25. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Dong M; Liu H; Tepp WH; Johnson EA; Janz R; Chapman ER Mol Biol Cell; 2008 Dec; 19(12):5226-37. PubMed ID: 18815274 [TBL] [Abstract][Full Text] [Related]
26. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A. Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505 [TBL] [Abstract][Full Text] [Related]
27. Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach. Muglia P; Hannestad J; Brandt C; DeBruyn S; Germani M; Lacroix B; Majoie M; Otoul C; Sciberras D; Steinhoff BJ; Van Laere K; Van Paesschen W; Webster E; Kaminski RM; Werhahn KJ; Toledo M Brain Commun; 2020; 2(2):fcaa183. PubMed ID: 33241213 [TBL] [Abstract][Full Text] [Related]
28. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. Russo E; Citraro R; Mula M Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199 [TBL] [Abstract][Full Text] [Related]
29. Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. Stahl SM J Clin Psychiatry; 2004 Sep; 65(9):1162-3. PubMed ID: 15367040 [TBL] [Abstract][Full Text] [Related]
30. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A. Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214 [TBL] [Abstract][Full Text] [Related]
31. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity. Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839 [TBL] [Abstract][Full Text] [Related]
32. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy. van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715 [TBL] [Abstract][Full Text] [Related]
33. Structure activity relationships of novel antiepileptic drugs. Mittapalli GK; Roberts E Curr Med Chem; 2014; 21(6):722-54. PubMed ID: 24251563 [TBL] [Abstract][Full Text] [Related]
34. Expression of SV2 isoforms during rodent brain development. Crèvecœur J; Foerch P; Doupagne M; Thielen C; Vandenplas C; Moonen G; Deprez M; Rogister B BMC Neurosci; 2013 Aug; 14():87. PubMed ID: 23937191 [TBL] [Abstract][Full Text] [Related]
35. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944 [TBL] [Abstract][Full Text] [Related]
36. 3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels. Collins I; Moyes C; Davey WB; Rowley M; Bromidge FA; Quirk K; Atack JR; McKernan RM; Thompson SA; Wafford K; Dawson GR; Pike A; Sohal B; Tsou NN; Ball RG; Castro JL J Med Chem; 2002 Apr; 45(9):1887-900. PubMed ID: 11960500 [TBL] [Abstract][Full Text] [Related]
37. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae. Madeo M; Kovács AD; Pearce DA J Biol Chem; 2014 Nov; 289(48):33066-71. PubMed ID: 25326386 [TBL] [Abstract][Full Text] [Related]
38. Brivaracetam augments short-term depression and slows vesicle recycling. Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103 [TBL] [Abstract][Full Text] [Related]
39. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. Carter RB; Wood PL; Wieland S; Hawkinson JE; Belelli D; Lambert JJ; White HS; Wolf HH; Mirsadeghi S; Tahir SH; Bolger MB; Lan NC; Gee KW J Pharmacol Exp Ther; 1997 Mar; 280(3):1284-95. PubMed ID: 9067315 [TBL] [Abstract][Full Text] [Related]
40. Brivaracetam for the treatment of epilepsy. Schulze-Bonhage A Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]